Cardiovascular Disease

SYM 2081 (Standard) is the analytical standard of SYM 2081 (HY-101310). This product is intended for research and analytical applications. SYM 2081 is a kainate receptor agonist. SYM 2081 is a substrate of EAAT1 (Km of 54 μM). SYM 2081 inhibits EAAT2-mediated glutamate transport (Kb is 3.4 μM in Xenopus oocytes), modulates Apoptotic signaling pathways (increases Bcl-2 and decreases Bax/caspase-3 expression). SYM 2081 exhibits neuroprotective activity. SYM 2081 can be used in the study of hypoxic-ischemic brain damage and inflammatory or neuropathic pain.

(±)-Clopidogrel hydrochloride is an antithrombotic agent that is ADP-selective and orally available. (±)-Clopidogrel hydrochloride inhibits platelet aggregation by inhibiting the binding of ADP to its platelet receptors.

L-Palmitoylcarnitine-d₉ is deuterium labeled L-Palmitoylcarnitine. L-Palmitoylcarnitine, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine inhibits K_ATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2.

ALT-946 is an orally active inhibitor of the advanced glycation end product (AGE) formation pathway. ALT-946 blocks the formation of AGE-protein cross-links, reduces the accumulation of AGE in renal tissues, alleviates increased albuminuria and elevated glomerular filtration rate, prevents glomerulosclerosis, ameliorates medullary tubulointerstitial lesions, and reduces cortical tubular degeneration. ALT-946 can be used in research related to diabetic nephropathy and diabetic cardiovascular diseases.

2-Hydroxy-3′-O-methyladenosine is a synthetic intermediate product that can be used in the research of ischemic heart disease, cerebrovascular disease, kidney disease, inflammatory allergies and other diseases. 2-phenylamino-N6,2'-O-dimethyladenosine produced from 2-Hydroxy-3′-O-methyladenosine is an inhibitor of adenosine deaminase with a Ki of 13 nM.

SKP-451 is an ATP-sensitive potassium (K⁺) channel agonist. SKP-451 activates the ATP-sensitive K⁺ channels, promotes the efflux of K⁺, causes membrane hyperpolarization, and inhibits the influx of Ca²⁺, thereby relaxing the vascular smooth muscle. SKP-451 relaxs the canine coronary artery, rabbit basilar artery, and vertebral artery. SKP-451 also reduces the mean arterial blood pressure of conscious spontaneously hypertensive rats (SHR). SKP-451 is promising for research of cardiovascular diseases.

Ethaverine hydrobromide is a Papaverine derivative and vasodilator. Ethaverine hydrobromide inhibits Phosphodiesterase, Tyrosine hydroxylase, and MAO-B. Ethaverine hydrobromide blocks L-type Ca²⁺ channels, reduces intracellular Ca²⁺ levels, inhibits platelet adhesion and aggregation, regulates cardiac conduction and heart rate, and increases peripheral and cerebral blood flow. Ethaverine hydrobromide alters cochlear microcirculation, intracochlear Po₂, CM potential, and EP in guinea pigs, and induces transient hypotension. Ethaverine hydrobromide is used in the research of peripheral vascular diseases.

Zacopride (hydrochloride) (Standard) is the analytical standard of Zacopride (hydrochloride). This product is intended for research and analytical applications. Zacopride hydrochloride is a highly potent 5-HT3 receptor antagonist with Kis of 0.38 and 373 nM for 5-HT3 and 5-HT4 receptor, respectively. Zacopride hydrochloride is also a moderate IK1 channel agonist. Zacopride hydrochloride exerts significant antiarrhythmic and cardiac protective effects.

P2Y12 antagonist 1 (compound 26) is a P2Y12 receptor antagonist with a Ki of 3.13 μM. P2Y12 antagonist 1 can be used to inhibit platelet aggregation and is a potential antithrombotic agent.

BMS-687453 (Standard) is the analytical standard of BMS-687453 (HY-10678). This product is intended for research and analytical applications. BMS-687453 is a potent and selective PPARα agonist, with an EC₅₀ and IC₅₀ of 10 nM and 260 nM for human PPARα and 4100 nM and >15000 nM for PPARγ in PPAR-GAL4 transactivation assays.

PD 123319 ditrifluoroacetate (Standard) is the analytical standard of PD 123319 ditrifluoroacetate (HY-10259A). This product is intended for research and analytical applications. PD 123319 ditrifluoroacetate is a potent, selective AT2 angiotensin II receptor antagonist with IC₅₀ of 34 nM.

DL-m-Tyrosine (Standard) is the analytical standard of DL-m-Tyrosine (HY-W001940). This product is intended for research and analytical applications. DL-m-Tyrosine is a non-protein amino acid. DL-m-Tyrosine inhibits microbial growth and spore formation. DL-m-Tyrosine also inhibits root growth in various plants, such as lettuce and Arabidopsis. DL-m-Tyrosine, when used in combination with Carbidopa (HY-B0311), has a potent antihypertensive effect. DL-m-Tyrosine can be used in research on biopesticide design.

Fenquizone (MG-13054) (Standard) is the analytical standard of Fenquizone (HY-126179). This product is intended for research and analytical applications. Fenquizone is an orally active diuretic. Fenquizone acts primarily on the diluting segment of the nephron cortex, similar to thiazide diuretics. Fenquizone demonstrates diuretic and natriuretic potency and duration of action comparable to thiazide diuretics but weaker than loop diuretics.​ Fenquizone reduces CH₂O without affecting TCH₂O, does not increase calcium/phosphate excretion, and has no loop or collecting duct effects. Fenquizone is used in the study of edema and hypertension.

GR148672X (Standard) is the analytical standard of GR148672X (HY-110390). This product is intended for research and analytical applications. GR148672X is a triacyglycerol hydrolase (TGH) inhibitor with an IC₅₀ of 4 nM extracted from patent WO 2001016358 A2.

NTE-122 (dihydrochloride) is an inhibitor of acyl-CoA:cholesterol acyltransferase (ACAT), with the IC₅₀ in liver and aorta of cholesterol-fed rabbits of 7.6nM, 4.4nM and 9.6 nM, respectively, that plays an important role in atherosclerosis.

Centhaquin (Standard) is the analytical standard of Centhaquin. This product is intended for research and analytical applications. Centhaquine (Centhaquin; PMZ-2010) is a novel agent has the potential for treatment of haemorrhagic shock. Centhaquine (Centhaquin; PMZ-2010) can augment cardiac output, reduce systemic vascular resistance in haemorrhagic models.

Ripasudil (Standard) is the analytical standard of Ripasudil. This product is intended for research and analytical applications. Ripasudil (K-115) is a specific inhibitor of ROCK, with IC50s of 19 and 51 nM for ROCK2 and ROCK1, respectively.

MSD-D is a potent and frequency-dependent Kv1.5 channel inhibitor with an IC₅₀ value of 0.5 μM. MSD-D is promising for research of atrial-selective class III antiarrhythmics.

Wy 27127 is a potent and selective α₂-adrenergic receptor antagonist. Wy 27127 competitively blocks α₂-adrenergic receptors, interrupts the negative feedback loop of sympathetic nerve endings, enhances stimulus-evoked norepinephrine release, and blocks agonist-induced inhibition of vas deferens contraction. Wy 27127 shows weak antagonistic effects on α₁ receptors, and exhibits no significant antagonistic activity against 5-hydroxytryptamine, muscarinic, presynaptic dopamine, histamine or β₁-adrenergic receptors in vitro. Wy 27127 blocks saphenous vein contraction mediated by postsynaptic α₂-adrenergic receptor agonists. Wy 27127 is applicable to studies related to sympathetic neurotransmission and vascular adrenergic responses.

Antiarrhythmic agent-2 is a nonspecific Ca²⁺ inward current blocker that inhibits ionic currents in sensory neuron membranes. Antiarrhythmic agent-2 can be used in the study of cardiovascular diseases, such as arrhythmias.